Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of CT032 anti-CD19 autologous CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphoma
CTR20191134Phase 2Terminated
- Sponsor
- CARsgen Therapeutics
- Start
- Oct 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CT032 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, transformed (t-FL), sponsored by CARsgen Therapeutics. Started Oct 2019; status: terminated.
02
Drugs
CT032
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma, transformed (t-FL)
Beyond the preview
Go deeper on CTR20191134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191134.